Revagenix Doses First Participant in Phase 1 Trial of Rev-56, an Inhaled Therapy for Non-CF Bronchiectasis

Revagenix Expands Executive Team, Names Peter Smith, Ph.D., Chief Scientific Officer as Lead Program Enters the Clinic